<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p106" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_106{left:285px;bottom:860px;letter-spacing:-0.32px;word-spacing:0.06px;}
#t2_106{left:285px;bottom:827px;letter-spacing:-0.27px;}
#t3_106{left:36px;bottom:25px;letter-spacing:0.07px;word-spacing:0.01px;}
#t4_106{left:341px;bottom:30px;}
#t5_106{left:348px;bottom:25px;letter-spacing:0.11px;}
#t6_106{left:377px;bottom:30px;}
#t7_106{left:381px;bottom:25px;letter-spacing:0.07px;word-spacing:-0.1px;}
#t8_106{left:540px;bottom:30px;}
#t9_106{left:546px;bottom:25px;letter-spacing:0.07px;}
#ta_106{left:44px;bottom:77px;letter-spacing:0.1px;word-spacing:-0.05px;}
#tb_106{left:44px;bottom:63px;letter-spacing:0.1px;}
#tc_106{left:996px;bottom:873px;letter-spacing:-0.1px;}
#td_106{left:1043px;bottom:853px;letter-spacing:-0.22px;word-spacing:0.13px;}
#te_106{left:1093px;bottom:833px;letter-spacing:-0.09px;}
#tf_106{left:1118px;bottom:47px;letter-spacing:0.32px;}
#tg_106{left:1121px;bottom:28px;letter-spacing:0.19px;word-spacing:-0.15px;}
#th_106{left:36px;bottom:748px;letter-spacing:-0.18px;}
#ti_106{left:36px;bottom:729px;letter-spacing:-0.1px;}
#tj_106{left:41px;bottom:711px;}
#tk_106{left:58px;bottom:711px;letter-spacing:-0.1px;word-spacing:0.01px;}
#tl_106{left:58px;bottom:693px;letter-spacing:-0.09px;}
#tm_106{left:58px;bottom:674px;letter-spacing:-0.09px;}
#tn_106{left:41px;bottom:656px;}
#to_106{left:58px;bottom:656px;letter-spacing:-0.1px;word-spacing:0.01px;}
#tp_106{left:58px;bottom:638px;letter-spacing:-0.09px;}
#tq_106{left:41px;bottom:619px;}
#tr_106{left:58px;bottom:619px;letter-spacing:-0.17px;word-spacing:0.07px;}
#ts_106{left:36px;bottom:587px;letter-spacing:-0.1px;}
#tt_106{left:80px;bottom:595px;letter-spacing:-0.13px;}
#tu_106{left:41px;bottom:569px;}
#tv_106{left:58px;bottom:569px;letter-spacing:-0.09px;}
#tw_106{left:58px;bottom:550px;letter-spacing:-0.09px;}
#tx_106{left:58px;bottom:532px;letter-spacing:-0.09px;}
#ty_106{left:58px;bottom:514px;letter-spacing:-0.1px;}
#tz_106{left:41px;bottom:495px;}
#t10_106{left:58px;bottom:495px;letter-spacing:-0.11px;word-spacing:0.01px;}
#t11_106{left:58px;bottom:477px;letter-spacing:-0.1px;}
#t12_106{left:36px;bottom:445px;letter-spacing:-0.24px;word-spacing:0.15px;}
#t13_106{left:277px;bottom:453px;letter-spacing:-0.13px;}
#t14_106{left:41px;bottom:427px;}
#t15_106{left:58px;bottom:427px;letter-spacing:-0.13px;word-spacing:0.03px;}
#t16_106{left:63px;bottom:408px;}
#t17_106{left:76px;bottom:408px;letter-spacing:-0.09px;}
#t18_106{left:77px;bottom:390px;letter-spacing:-0.09px;}
#t19_106{left:488px;bottom:398px;}
#t1a_106{left:501px;bottom:390px;letter-spacing:-0.09px;}
#t1b_106{left:77px;bottom:372px;letter-spacing:-0.1px;}
#t1c_106{left:260px;bottom:379px;}
#t1d_106{left:63px;bottom:353px;}
#t1e_106{left:76px;bottom:353px;letter-spacing:-0.09px;}
#t1f_106{left:77px;bottom:335px;letter-spacing:-0.09px;}
#t1g_106{left:63px;bottom:317px;}
#t1h_106{left:76px;bottom:317px;letter-spacing:-0.09px;}
#t1i_106{left:77px;bottom:298px;letter-spacing:-0.09px;}
#t1j_106{left:973px;bottom:306px;}
#t1k_106{left:63px;bottom:280px;}
#t1l_106{left:76px;bottom:280px;letter-spacing:-0.09px;}
#t1m_106{left:881px;bottom:288px;}
#t1n_106{left:41px;bottom:262px;}
#t1o_106{left:58px;bottom:262px;letter-spacing:-0.09px;}
#t1p_106{left:58px;bottom:243px;letter-spacing:-0.2px;word-spacing:0.1px;}
#t1q_106{left:41px;bottom:225px;}
#t1r_106{left:58px;bottom:225px;letter-spacing:-0.1px;word-spacing:0.01px;}
#t1s_106{left:58px;bottom:207px;letter-spacing:-0.09px;}
#t1t_106{left:58px;bottom:188px;letter-spacing:-0.09px;}
#t1u_106{left:686px;bottom:196px;letter-spacing:-0.14px;}
#t1v_106{left:36px;bottom:131px;}
#t1w_106{left:46px;bottom:125px;letter-spacing:0.12px;word-spacing:-0.05px;}
#t1x_106{left:45px;bottom:108px;letter-spacing:0.09px;}
#t1y_106{left:1091px;bottom:95px;letter-spacing:-0.11px;}
#t1z_106{left:414px;bottom:778px;letter-spacing:0.4px;word-spacing:-0.23px;}
#t20_106{left:772px;bottom:786px;letter-spacing:-0.12px;}
#t21_106{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_106{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s1_106{font-size:9px;font-family:ArialMT_5tg;color:#000;}
.s2_106{font-size:5px;font-family:ArialMT_5tg;color:#000;}
.s3_106{font-size:12px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_106{font-size:17px;font-family:ArialMT_5tg;color:#0065A4;}
.s5_106{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s6_106{font-size:17px;font-family:Arial-BoldMT_jz;color:#000;}
.s7_106{font-size:17px;font-family:Webdings_k6;color:#000;}
.s8_106{font-size:14px;font-family:Arial-BoldMT_5te;color:#000;}
.s9_106{font-size:17px;font-family:SymbolMT_ka;color:#000;}
.sa_106{font-size:12px;font-family:ArialMT_5tg;color:#000;}
.sb_106{font-size:15px;font-family:ArialMT_5tg;color:#000;}
.sc_106{font-size:15px;font-family:ArialMT_5tg;color:#0065A4;}
.sd_106{font-size:17px;font-family:Arial-BoldMT_5te;color:#0065A4;}
.se_106{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts106" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: Arial-BoldMT_jz;
	src: url("fonts/Arial-BoldMT_jz.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

@font-face {
	font-family: SymbolMT_ka;
	src: url("fonts/SymbolMT_ka.woff") format("woff");
}

@font-face {
	font-family: Webdings_k6;
	src: url("fonts/Webdings_k6.woff") format("woff");
}

</style>
<div id="pg106Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg106" style="-webkit-user-select: none;"><object width="1210" height="935" data="106/106.svg" type="image/svg+xml" id="pdf106" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_106" class="t s0_106">NCCN Guidelines Version 4.2024 </span>
<span id="t2_106" class="t s0_106">Head and Neck Cancers </span>
<span id="t3_106" class="t s1_106">Version 4.2024, 5/1/2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t4_106" class="t s2_106">® </span>
<span id="t5_106" class="t s1_106">(NCCN </span>
<span id="t6_106" class="t s2_106">® </span>
<span id="t7_106" class="t s1_106">), All rights reserved. NCCN Guidelines </span>
<span id="t8_106" class="t s2_106">® </span>
<span id="t9_106" class="t s1_106">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="ta_106" class="t s3_106">Note: All recommendations are category 2A unless otherwise indicated. </span>
<span id="tb_106" class="t s3_106">Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged. </span>
<span id="tc_106" class="t s4_106">NCCN Guidelines Index </span>
<span id="td_106" class="t s4_106">Table of Contents </span>
<span id="te_106" class="t s4_106">Discussion </span>
<span id="tf_106" class="t s5_106">RAD-A </span>
<span id="tg_106" class="t s5_106">2 OF 7 </span>
<span id="th_106" class="t s6_106">Techniques/Dosing </span>
<span id="ti_106" class="t s5_106">• IMRT </span>
<span id="tj_106" class="t s7_106"></span><span id="tk_106" class="t s5_106">IMRT is preferred in reducing long-term toxicity in oropharyngeal, nasal cavity, paranasal sinus, salivary gland, and nasopharyngeal </span>
<span id="tl_106" class="t s5_106">cancers by reducing the dose to salivary glands, temporal lobes, auditory structures (including cochlea), and optic structures. IMRT is </span>
<span id="tm_106" class="t s5_106">preferred for thyroid cancers because of its ability to spare the larynx, brachial plexus, and esophagus. </span>
<span id="tn_106" class="t s7_106"></span><span id="to_106" class="t s5_106">The application of IMRT to other sites (eg, oral cavity, larynx, hypopharynx) is preferred and may be used at the discretion of treating </span>
<span id="tp_106" class="t s5_106">physicians. </span>
<span id="tq_106" class="t s7_106"></span><span id="tr_106" class="t s5_106">Helical tomotherapy and VMAT are advanced forms of IMRT. </span>
<span id="ts_106" class="t s5_106">• PBT </span>
<span id="tt_106" class="t s8_106">12-32 </span>
<span id="tu_106" class="t s7_106"></span><span id="tv_106" class="t s5_106">Achieving highly conformal dose distributions is especially important for patients whose primary tumors are periocular in location and/ </span>
<span id="tw_106" class="t s5_106">or invade the orbit, skull base, and/or cavernous sinus; extend intracranially or exhibit extensive perineural invasion; and who are being </span>
<span id="tx_106" class="t s5_106">treated with curative intent and/or who have long life expectancies following treatment. Nonrandomized single-institution clinical reports </span>
<span id="ty_106" class="t s6_106" data-mappings='[[51,"ffi"],[92,"fi"]]'>and systematic comparisons demonstrate safety and eﬃcacy of PBT in the above-mentioned speciﬁc clinical scenarios. </span>
<span id="tz_106" class="t s7_106"></span><span id="t10_106" class="t s5_106">Proton therapy can be considered when normal tissue constraints cannot be met by photon-based therapy, or when photon-based therapy </span>
<span id="t11_106" class="t s5_106">causes compromise of standard radiation dosing to tumor or postoperative volumes. </span>
<span id="t12_106" class="t s5_106">• IMRT, PBT, and Fractionation </span>
<span id="t13_106" class="t s8_106">33-35 </span>
<span id="t14_106" class="t s7_106"></span><span id="t15_106" class="t s5_106">A number of ways exist to integrate IMRT or PBT, target volume dosing, and fractionation. </span>
<span id="t16_106" class="t s9_106">◊ </span><span id="t17_106" class="t s6_106" data-mappings='[[25,"ff"]]'>The SIB technique uses diﬀerential “dose painting” (66–72 Gy to gross disease; 44–63 Gy to subclinical disease) for each fraction of </span>
<span id="t18_106" class="t s5_106">treatment throughout the entire course of radiation. </span>
<span id="t19_106" class="t s8_106">4 </span>
<span id="t1a_106" class="t s5_106">SIB is commonly used in the conventional (5 fractions/wk) and the “6 fractions/wk </span>
<span id="t1b_106" class="t s5_106">accelerated” schedule. </span>
<span id="t1c_106" class="t s8_106">5 </span>
<span id="t1d_106" class="t s9_106">◊ </span><span id="t1e_106" class="t s6_106">The sequential (SEQ) technique typically delivers the initial (lower dose) phase (weeks 1–5) followed by the high-dose boost volume </span>
<span id="t1f_106" class="t s5_106">phase (weeks 6–7) using 2–3 separate dose plans, and is commonly applied in standard fractionation and hyperfractionation. </span>
<span id="t1g_106" class="t s9_106">◊ </span><span id="t1h_106" class="t s6_106" data-mappings='[[62,"fi"]]'>The concomitant boost accelerated schedule may utilize a “modiﬁed SEQ” dose plan by delivering the dose to the subclinical targets </span>
<span id="t1i_106" class="t s5_106">once a day for 6 weeks, and a separate boost dose plan as a second daily fraction for the last 12 treatment days. </span>
<span id="t1j_106" class="t s8_106">6 </span>
<span id="t1k_106" class="t s9_106">◊ </span><span id="t1l_106" class="t s5_106">Another accelerated approach, aside from concomitant boost, is to simply treat 6 fractions per week. </span>
<span id="t1m_106" class="t s8_106">5 </span>
<span id="t1n_106" class="t s7_106"></span><span id="t1o_106" class="t s5_106">Altered fractionation may be used for select patients with comorbidities who are not good candidates for 6–7 weeks of adjuvant RT or </span>
<span id="t1p_106" class="t s5_106">systemic therapy/RT. </span>
<span id="t1q_106" class="t s7_106"></span><span id="t1r_106" class="t s6_106" data-mappings='[[47,"fi"]]'>Altered fractionation has not proven to be beneﬁcial in the context of concurrent chemotherapy. The best available evidence is that the </span>
<span id="t1s_106" class="t s6_106" data-mappings='[[4,"fi"],[44,"fi"],[125,"fi"]]'>beneﬁt of accelerated fractionation is speciﬁc to hyperfractionation, hazard ratio (HR) = 0.83 for overall survival. The beneﬁt of other </span>
<span id="t1t_106" class="t s5_106">methods of altered fractionation is not clearly advantageous on meta-analysis. </span>
<span id="t1u_106" class="t s8_106">36 </span>
<span id="t1v_106" class="t sa_106">a </span>
<span id="t1w_106" class="t sb_106">For additional resources regarding the technical details of radiation, see the American College of Radiology Guidelines: </span>
<span id="t1x_106" class="t sc_106">https://www.acr.org/Clinical-Resources/Practice-Parameters-and-Technical-Standards </span>
<span id="t1y_106" class="t sd_106">Continued </span>
<span id="t1z_106" class="t s6_106">PRINCIPLES OF RADIATION TECHNIQUES </span>
<span id="t20_106" class="t s8_106">a,9 </span>
<span id="t21_106" class="t se_106">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
